Alaunos Therapeutics (TCRT) Capital Expenditures (2009 - 2025)

Alaunos Therapeutics has reported Capital Expenditures for 16 years, with the latest figure at $1000.0 in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Dec 2025 stood at $1000.0 (changed N/A YoY), and the FY2025 full-year result was $98000.0, changed N/A from the prior year.
• Capital Expenditures for Q4 2025 stood at $1000.0, roughly flat from $1000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $1.9 million in Q2 2021, with the low at $1000.0 in Q3 2023.
• Historically, Capital Expenditures has averaged $311416.7 across 4 years, with a median of $88500.0 in 2022.
• Annual changes were most pronounced in 2021 — Capital Expenditures jumped 272.71% — and 2022, when it plunged 97.02%.
• Alaunos Therapeutics' Capital Expenditures stood at $359000.0 in 2021, then slumped by 67.69% to $116000.0 in 2022, then slumped by 99.14% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2025.
• The last three Capital Expenditures figures came in at $1000.0 (Q4 2025), $1000.0 (Q3 2023), and $135000.0 (Q2 2023), per Business Quant data.